Global /China /Healthcare /Biotechnology /9887

Nanjing Leads Biolabs Co., Ltd.

9887

• SHEK: 9887 • Delayed

80.00HKD -1.1%

10.21 USD

As of 13 June 2026, Nanjing Leads Biolabs Co., Ltd. has a market cap of $2.04B USD, ranking #6946 globally and #1681 in China. It ranks #557 in the Healthcare sector, and #104 in the Biotechnology industry.

Global Rank

6946

Country Rank

1681

Sector Rank

557

Industry Rank

104

Key Stats

Market Cap

$2.04BUSD

15.97B HKD

Enterprise Value

$1.86BUSD

14.56B HKD

Revenue (TTM)

$25.17MUSD

197.25M HKD

EBITDA (TTM)

-$24.75MUSD

-193.95M HKD

Net Income (TTM)

-$30.02MUSD

-235.27M HKD

EBITDA Margin

-98%

Profit Margin

-119%

PS Ratio

81.0

PB Ratio

11.3

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Xiaoqiang Kang open_in_new

Founded

2012

Website

leadsbiolabs.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.1%	-2.3%	7.4%	33%	36%	57%	-26%	-26%	-26%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	9887 ISIN: CNE1000070H8 Shares Out.: Shares Outstanding: 196.335M¹ Shares Float: 124.258M² TV: TradingView: HKEX: 9887 SA: Stock Analysis: HKG: 9887 YF: Yahoo Finance: 9887.HK GF: Google Finance: HKG: 9887 BA: Barron's: 9887 MS: Morningstar: XHKG: 09887	80.00 HKD	TV: TradingView: HKEX: 9887 SA: Stock Analysis: HKG: 9887 YF: Yahoo Finance: 9887.HK GF: Google Finance: HKG: 9887 BA: Barron's: 9887 MS: Morningstar: XHKG: 09887

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nanjing Leads Biolabs Co., Ltd.

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay. The company was founded in 2012 and is headquartered in Nanjing, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 756%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 498%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 293%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 260%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 247%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 230%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 9K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 8K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 2K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 2K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 2K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 2K%	37.2	Switzerland

chevron_leftBack